Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics. Iclaprim exhibits potent activity against many genera of staphylococci including MSSA and MRSA.Learn More
Motif intends to build a portfolio of novel antibiotics by licensing drug candidates from organizations specializing in antibacterial research. Motif is pursuing several programs in various stages of development.Learn More
The Antibiotic Crisis
So-called “superbugs” are emerging faster than new, effective antibiotics are being developed. The medical need for new treatments, especially for those with different mechanisms and resistance patterns, is widely recognized.Learn More